Palmer CN, Hsu MH, Griffin HJ, Johnson EF. Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem. 1995;270(27):16114–21.

Article  CAS  PubMed  Google Scholar 

Zhang Z, Xu Y, Xu Q, Hou Y. PPARgamma against tumors by different signaling pathways. Onkologie. 2013;36(10):598–601.

CAS  PubMed  Google Scholar 

Gou Q, et al. PPARgamma inhibited tumor immune escape by inducing PD-L1 autophagic degradation. Cancer Sci. 2023;114(7):2871–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu L, et al. PPARgamma agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape. J Cell Biochem. 2023;124(8):1145–54.

Article  CAS  PubMed  Google Scholar 

Xu Y, et al. SULT1E1 inhibits cell proliferation and invasion by activating PPARgamma in breast cancer. J Cancer. 2018;9(6):1078–87.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, et al. VSP-17, a New PPARgamma Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin. Molecules. 2018. https://doi.org/10.3390/molecules23010121.

Article  PubMed  PubMed Central  Google Scholar 

Cao LQ, et al. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibits hepatoma cell growth via downregulation of SEPT2 expression. Cancer Lett. 2015;359(1):127–35.

Article  CAS  PubMed  Google Scholar 

To KKW, Wu WKK, Loong HHF. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy. Eur J Pharmacol. 2018;823:19–26.

Article  CAS  PubMed  Google Scholar 

Mehus AA, et al. Activation of PPARgamma and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS ONE. 2020;15(8): e0237976.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tashiro Y, et al. Ischemia reperfusion-induced metastasis is resistant to PPARgamma agonist pioglitazone in a murine model of colon cancer. Sci Rep. 2020;10(1):18565.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hernandez-Quiles M, et al. TRIB3 Modulates PPARgamma-Mediated Growth Inhibition by Interfering with the MLL Complex in Breast Cancer Cells. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms231810535.

Article  PubMed  PubMed Central  Google Scholar 

Hua TNM, et al. PPARgamma-mediated ALDH1A3 suppression exerts anti-proliferative effects in lung cancer by inducing lipid peroxidation. J Recept Signal Transduct Res. 2018;38(3):191–7.

Article  CAS  PubMed  Google Scholar 

Chang HK, et al. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists in HeLa cells. Biochem Biophys Res Commun. 2017;482(4):843–8.

Article  CAS  PubMed  Google Scholar 

Pu Z, Zhu M, Kong F. Telmisartan prevents proliferation and promotes apoptosis of human ovarian cancer cells through upregulating PPARgamma and downregulating MMP-9 expression. Mol Med Rep. 2016;13(1):555–9.

Article  CAS  PubMed  Google Scholar 

Xu YY, et al. PPARgamma inhibits breast cancer progression by upregulating PTPRF expression. Eur Rev Med Pharmacol Sci. 2019;23(22):9965–77.

PubMed  Google Scholar 

Yamashita H, et al. Repression of transcription factor AP-2 alpha by PPARgamma reveals a novel transcriptional circuit in basal-squamous bladder cancer. Oncogenesis. 2019;8(12):69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou Y, Moreau F, Chadee K. PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65. Nat Commun. 2012;3:1300.

Article  PubMed  Google Scholar 

Hou Y, et al. PPARgamma E3 ubiquitin ligase regulates MUC1-C oncoprotein stability. Oncogene. 2014;33(49):5619–25.

Article  CAS  PubMed  Google Scholar 

Fujita M, et al. Cytotoxicity of 15-deoxy-Delta(12,14)-prostaglandin J(2) through PPARgamma-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma. Int J Med Sci. 2012;9(7):555–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, et al. Bergenin inhibits bladder cancer progression via activating the PPARgamma/PTEN/Akt signal pathway. Drug Dev Res. 2021;82(2):278–86.

Article  CAS  PubMed  Google Scholar 

Ai X, et al. Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway. BMC Cancer. 2018;18(1):407.

Article  PubMed  PubMed Central  Google Scholar 

Han M, et al. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARgamma. Biomed Pharmacother. 2018;103:272–83.

Article  CAS  PubMed  Google Scholar 

Zou Y, et al. Polyunsaturated Fatty Acids from Astrocytes Activate PPARgamma Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discov. 2019;9(12):1720–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rinaldi L, et al. Loss of Dnmt3a and Dnmt3b does not affect epidermal homeostasis but promotes squamous transformation through PPAR-gamma. Elife. 2017. https://doi.org/10.7554/eLife.21697.

Article  PubMed  PubMed Central  Google Scholar 

Musicant AM, et al. CRTC1/MAML2 directs a PGC-1alpha-IGF-1 circuit that confers vulnerability to PPARgamma inhibition. Cell Rep. 2021;34(8): 108768.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng S, et al. PPARgamma inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. J Cell Mol Med. 2019;23(5):3724–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sippel TR, et al. Activation of PPARgamma in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFbeta1. Mol Cancer Res. 2019;17(8):1748–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khandekar MJ, et al. Noncanonical agonist PPARgamma ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. Proc Natl Acad Sci U S A. 2018;115(3):561–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu RZ, et al. The FABP12/PPARgamma pathway promotes metastatic transformation by inducing epithelial-to-mesenchymal transition and lipid-derived energy production in prostate cancer cells. Mol Oncol. 2020;14(12):3100–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, et al. A novel multifunctional mitochondrion-targeting NIR fluorophore probe inhibits tumour proliferation and metastasis through the PPARgamma/ROS/beta-catenin pathway. Eur J Med Chem. 2023;258: 115435.

Article  CAS  PubMed  Google Scholar 

Forootan FS, et al. Fatty acid activated PPARgamma promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter. Oncotarget. 2016;7(8):9322–39.

Article  PubMed  PubMed Central  Google Scholar 

Wu B, et al. PPARgamma inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner. Int J Biol Sci. 2020;16(9):1526–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu B, et al. Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. Oncoimmunology. 2018;7(11): e1500107.

Article  PubMed  PubMed Central  Google Scholar 

Xiong Z, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023;72(9):1758–73.

Article  CAS  PubMed  Google Scholar 

Erra Diaz F, et al. Concomitant inhibition of PPARgamma and mTORC1 induces the differentiation of human monocytes into highly immunogenic dendritic cells. Cell Rep. 2023;42(3): 112156.

Article  CAS  PubMed  Google Scholar 

Prat M, et al. PPARgamma activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression. J Immunother Cancer. 2023. https://doi.org/10.1136/jitc-2023-007031.

Article  PubMed  PubMed Central